Therefore, the suppression of intermittent hypoxia-induced CCR5 expression or to inhibit the CCR5 function by antagonists could be a reasonable method to avoid the progression of atherosclerosis in OSA patients. This evidence concerns the gene CCR5 and atherosclerosis.